Research Topics
| S F SlovinSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancerMichael J Morris
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:679-83. 2002..Current randomized trials are using the highest daily dose established in this study given by shorter infusion periods (i.e., 7 mg/kg/day for 5-7 days) to enhance the antitumor activity of standard cytotoxic drugs...- Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapySusan F Slovin
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 11:8669-73. 2005.... - Violaceous exanthem as a manifestation of metastatic prostate cancer in skinSusan F Slovin
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 67:420. 2006 
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancerSusan F Slovin
Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, New York 10065, USA Electronic address
Vaccine 31:943-9. 2013..PSMA-VRP was well-tolerated at both doses. While there did not appear to be clinical benefit nor robust immune signals at the two doses studied, neutralizing antibodies were produced by both cohorts suggesting that dosing was suboptimal...- Chemotherapy and immunotherapy combination in advanced prostate cancerSusan Slovin
Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Adv Hematol Oncol 10:90-100. 2012..Patient characteristics, prostate cancer disease stage, and treatment history also may influence the response to combined therapy. Advances in biomarker validation and trial design are needed to efficiently investigate these issues... - Immunologic targeting: how to channel a minimal response for maximal outcomeSusan F Slovin
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Curr Opin Urol 16:179-85. 2006.... - Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancerSusan F Slovin
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Immunol Immunother 54:694-702. 2005..The results justify the inclusion of TF(c) at a dose of 1 microg as a relevant antigenic target in a multivalent phase II vaccine trial in patients in the high-risk minimal disease state... - A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21Susan F Slovin
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Vaccine 23:3114-22. 2005..Compared with a subsequent trial with the same bivalent vaccine plus QS-21 at the maximal tolerated dose of 100 microg, the 5000 microg dose of GPI-0100 produced comparable antibody titers... 
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigenSusan F Slovin
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Expert Opin Ther Targets 9:561-70. 2005..This review serves to present unique approaches in vaccine development which can induce immunological responsiveness with potential impact on disease progression and to introduce PSMA as a potential target for multimodality therapies...- Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in manS F Slovin
Division of Genitourinary Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 96:5710-5. 1999.... - Carbohydrate vaccines as immunotherapy for cancerSusan F Slovin
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
Immunol Cell Biol 83:418-28. 2005..The approaches for synthesis, conjugation, clinical administration and immunological potential are discussed... - Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto RicoSusan F Slovin
Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10021, USA
IDrugs 8:710-2. 2005 - Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?Susan F Slovin
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Urol 3:138-44. 2006..This review outlines the difficulties in treating this disease, both at the time of diagnosis and in the metastatic setting, and focuses on an area of research that remains challenging to both the researcher and clinician... - Prostate-specific membrane antigen vaccines: naked DNA and protein approachesSusan F Slovin
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
Clin Prostate Cancer 4:118-23. 2005..This review serves to present unique approaches in vaccine development that can induce immunologic responsiveness to PSMA with potential impact on disease progression... - Emerging role of immunotherapy in the management of prostate cancerSusan F Slovin
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Oncology (Williston Park) 21:326-33; discussion 334, 338, 346-8. 2007..This review explores the challenges now faced in establishing a role for immune therapies for prostate cancer treatment... - Cancer immunotherapeutics meetingSusan F Slovin
Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10021, USA
Expert Opin Investig Drugs 13:1645-50. 2004..Another goal of this meeting was to foster collaborations among investigators to facilitate and extend current research objectives... - A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"Susan F Slovin
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer Immunol Immunother 56:1921-30. 2007..No impact on PSA slope was detected. We address the relevance of the multivalent approach for prostate cancer treatment... - Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancerSusan F Slovin
Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Genitourin Cancer 7:E77-82. 2009..The secondary endpoint was to assess the efficacy of cetuximab in combination with doxorubicin as well as to determine the optimal biologic dose and the maximum tolerated dose... - Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunityS F Slovin
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Hematol Oncol Clin North Am 15:477-96. 2001..The varying approaches toward vaccine construction as treatment strategies for relapsed prostate cancer are described... - Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?Susan F Slovin
Sidney Kimmel Center for Prostate and Urologic Cancers, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
Expert Rev Anticancer Ther 8:465-74. 2008..However, no one approach has been able to show improved overall survival. This article reviews the current issues and potential resolutions as to how we might go forward in developing and interpreting immunologic trials... - Pitfalls or promise in prostate cancer immunotherapy-which is winning?Susan F Slovin
Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer J 14:26-34. 2008..This article is a review of the current issues and potential resolutions as to how we might go forward in developing and interpreting immunologic trials... - Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccineSusan F Slovin
Genitourinary Solid Tumor Service, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 21:4292-8. 2003.... - Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcomeSusan F Slovin
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Clin Adv Hematol Oncol 5:972-80. 2007..This review updates the status of prostate cancer vaccines as tools for induction of active immunity and discusses the issues relevant to their clinical trial development... - Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behaviorSusan F Slovin
Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Oncol 4:551-4. 2007..One should be alerted to this phenotype in a patient with large volume disease on biopsy or examination and a low PSA or PSA not in proportion to tumor burden... - Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancerMatthew D Galsky
Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 26:2147-54. 2008..This novel immunoconjugate has shown cytotoxic anti-prostate cancer activity. This study investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704... - DNA vaccines: an active immunization strategy for prostate cancerJedd D Wolchok
Clinical Immunology Services, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 30:659-66. 2003..We are currently conducting a phase I trial of human and mouse PSMA DNA vaccines in patients with recurrent prostate cancer, based on preclinical experiments described below... - Chemotherapy for androgen- independent prostate cancer: myth or realityW K Kelly
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 2:394-401. 2000..These data suggest that prostate cancer is not as resistant to chemotherapy as it was once thought to be... - The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinomaE J Sherman
Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer 91:841-53. 2001..Considering the potentially significant impact on total costs, DNM/IC data should be included in future cost-analysis studies of patients with AIPC and other diseases... - HER-2 profiling and targeting in prostate carcinomaMichael J Morris
Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer 94:980-6. 2002.... - Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castrationO Smaletz
Department of Medicine, Division of Solid Tumor, Memorial Sloan-Kettering Cancer Center, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA
Ann Oncol 14:1518-24. 2003..CONCLUSIONS: The phase II dose of BMS-247550 combined with EMP is 35 mg/m(2) over 3 h every 3 weeks. This combination is safe and >/= 50% post-therapy declines in PSA were seen in 11 of 12 patients (92%)... - Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Eur Urol 56:237-44. 2009..Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth... - Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf
Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 26:2959-65. 2008..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers... - Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Appl Immunohistochem Mol Morphol 13:6-13. 2005..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2... - Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working GroupHoward I Scher
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 22:537-56. 2004..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)... - Scrotal and penile papules and plaques as the initial manifestation of a cutaneous metastasis of adenocarcinoma of the prostate: case report and review of the literatureSteven Q Wang
Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Cutan Pathol 35:681-4. 2008..We also review the literature on this subject... - Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang
Howard Hughes Medical Institute, Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Mod Pathol 23:1104-12. 2010..B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas... - A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris
Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, NY 10065, USA
Ann Oncol 23:2714-9. 2012.... - Second-line chemotherapy for prostate cancer: patient characteristics and survivalKathleen W Beekman
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Clin Prostate Cancer 4:86-90. 2005..A sequential or continuous administration of therapy may optimize the care of this subset of symptomatic patients... - Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 13:1775-82. 2007..To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules... - Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Genitourin Cancer 7:51-7. 2009..This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC)... - Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stageR Houston Thompson
Department of Surgery, Urology Service, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Res 68:6054-8. 2008..These early results merit further investigation of this serum marker for potential diagnostic and prognostic purposes... - Dendritic cell vaccines--hopeful or hopeless?Susan F Slovin
Cancer Invest 21:969-70. 2003 - Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancerNancy A Dawson
Genitourinary Oncology Program, Greenebaum Cancer Institute, University of Maryland, Baltimore, Maryland 21201, USA
Urology 62:102-18. 2003..Patients enrolling in these trials need to be clearly informed of the limited expectations of these novel exploratory approaches... - Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumorSusan F Slovin
Cancer Invest 22:818-21. 2004